Form 4: Harvard Bioscience Director Katherine Eade Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Katherine Eade reports acquisition of 45,872 restricted stock units in Harvard Bioscience, Inc.
Summary
- On May 21, 2024, Katherine A. Eade, a director of Harvard Bioscience, Inc., acquired 45,872 restricted stock units.
- These restricted stock units vest fully on the earlier of the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and May 21, 2025.
- Following this transaction, Eade beneficially owns a total of 311,126 shares of common stock, which includes the restricted stock units and 265,254 shares already held.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies.
Stakeholder Impact
- The acquisition of restricted stock units by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date referenced for the Issuer's next Annual Meeting of Stockholders. |
| 05/21/2024 | Date of transaction: Acquisition of restricted stock units. |
| 05/21/2025 | Latest date for full vesting of restricted stock units. |
| 05/23/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.